Cellectar Biosciences, Inc. CLRB
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Cellectar Biosciences, Inc. (CLRB) is a healthcare company listed in the US with a market value of about $11M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -218%.
About Cellectar Biosciences
Cellectar Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 6 years in our data. Its share count rose by 1009% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$22M | -$45M | -$43M | -$32M | -$24M | -$15M |
| Free cash flow | -$23M | -$48M | -$33M | -$25M | -$23M | -$14M |
| EPS (diluted) | $-8.35 | $-41.89 | $-105.00 | $-135.30 | $-130.50 | $-552.00 |
| Net margin | — | — | — | — | — | — |
| ROIC | -202.9% | -276.6% | — | -328.4% | -64.9% | -21.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Cellectar Biosciences pay a dividend?
Not currently.
Is Cellectar Biosciences a good stock to buy?
We do not give buy or sell advice. Cellectar Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.